Compared with IL-12–treated tumors, combination-treated tumors had significantly lower levels of several proteins in the PI3K/AKT/mTOR and MAPK signaling pathways (all P < 0.05), which could be due to the influence of tumor cells in the vicinity. The gene discussed is MTOR; the disease is neoplasm.